Result of EGM (2965B)
13 4월 2012 - 7:30PM
UK Regulatory
TIDMABH
RNS Number : 2965B
Angel Biotechnology Holdings Plc
13 April 2012
For immediate release 13 April 2012
Angel Biotechnology Holdings plc
("Angel" or "the Company")
Result of Extraordinary General Meeting
Angel Biotechnology Holdings plc, (AIM:ABH), the
biopharmaceutical contract manufacturer, announces that at the
Company's Extraordinary General Meeting ("EGM") held today, the
resolution was duly passed. Further details of voting are set out
below.
As a result, the Company will now complete the Placing announced
on 19 March 2012 and issue 500,000,000 ordinary shares of 0.1 pence
each (the "Ordinary Shares") at a price 0.20 pence per share to
raise GBP1 million (before expenses).
The Company has applied for the new Ordinary Shares to be
admitted to trading on the AIM market of the London Stock Exchange
and trading will commence on Monday 16 April 2012.
The new Ordinary Shares will be credited as fully paid and will
rank pari passu with the existing Ordinary Shares, including the
right to receive all dividends and other distributions declared,
made or paid after the date of their issue.
For the purposes of the Disclosure and Transparency Rules, the
Company's total issued share capital following admission will
consist of 3,773,616,615 Ordinary Shares with one voting right per
share. The Company has no shares in treasury. The above figure may
be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company, under
the FSA's Disclosure and Transparency Rules.
The following is a summary of the votes cast including
proxies:
Votes for % Votes against % Total votes*
464,335,489 98.87 5,307,890 1.13 469,970,955
*Votes were cast in respect of 14.35% of shares in issue.
For further information:
Angel Biotechnology Holdings plc
Lorna Peers, Finance Director +44 (0) 131 445 6077
Stewart White, Acting CEO/Commercial Director
www.angelbio.com
Grant Thornton, Corporate Finance
Colin Aaronson / Melanie Frean / Elliot Berg +44 (0) 20 7383
5100
Hybridan LLP (Broker)
Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350
Media enquiries:
The Communications Portfolio Ltd
Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029
ariane.comstive@communications-portfolio.co.uk
Notes to Editors:
Angel Biotechnology Holdings plc is a full service contract
bio-manufacturing partner to biotechnology and pharmaceutical
companies worldwide. Angel specialises in advanced biologics
including biopharmaceutical proteins and cell therapies, such as
cellular vaccines and stem cells. At present, Angel's products are
principally used in pre-clinical studies and clinical trials with a
view to becoming the contract manufacturer of choice on a
continuing basis.
Drug development companies outsource their biopharmaceutical
manufacturing requirements to Angel to reduce their own capital
requirements and enable them to develop products more rapidly. In
addition, Angel provides complete regulatory services and
documentation to its customers while its manufacturing processes
adhere to the most stringent regulatory requirements. Products are
produced to current Good Manufacturing Practice (cGMP) standards as
required by the US Food and Drug Administration (FDA), and in
facilities that are certified to European standards by the
Medicines and Healthcare products Regulatory Agency (MHRA).
Its customers range from early-stage biotechnology companies
including ReNeuron plc and US-based Pathfinder Cell Therapy, to
established pharmaceutical companies such as Russian-based Materia
Medica Holdings.
Angel has two facilities: Pentlands Science Park near Edinburgh
where it employs 38 people, and a site in Cramlington, near
Newcastle-upon-Tyne, which is expected to employ up to 10 people by
the end of 2012.
More information is available at www.angelbio.com .
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
REGBKNDKKBKDCQD
Angel Biotechnology (LSE:ABH)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Angel Biotechnology (LSE:ABH)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
